Expert consensus on subcutaneous injection of targeted drugs for breast cancer

Title: Expert consensus on subcutaneous injection of targeted drugs for breast cancer
Edition: Original
Classification: Experts consensus
Field: Diagnosis and Treatment
Countries and regions: China
Guidelines users: Medical staff planning to implement subcutaneous injection of targeted drugs for breast cancer, including nursing managers, clinical nurses, doctors, etc
Evidence classification method: No
Development unit: Oncology Nursing Committee of Chinese Nursing Association
Registration time: 2024-02-09
Registration number: PREPARE-2024CN262
Purpose of the guideline: Innovations led by targeted drug discovery, research and development have drastically improved the outcome of patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer. Subcutaneous formulations of HER2-targeted therapies provided safe, efficient, convenient, and economic treatment modality for HER2-positive breast cancer. Meanwhile, there have been new demands on standardized use and management of subcutaneous administration to healthcare professionals. To help the clinical practice of breast cancer targeted therapy with subcutaneous injection, Chinese Nursing Association Oncology Committee established current consensus using a modified Delphi method and soliciting experts’ opinions on trastuzumab injection and fixed-dose combination of pertuzumab and trastuzumab for subcutaneous use, which are now available in China, covering pre-administration preparation, administration practice, post-administration observing and recording, adverse effects management, patient education and follow-up.